EIDX

ATTRibute-PN

Transthyretin amyloidosis (ATTR)

Pase 3 Initiation

Exp Date

2H 2020

Amp Volatility Score

N/A

Catalyst Info & Data Links

TITLE: ATTRibute-PN  for Transthyretin amyloidosis (ATTR) Phase 3 Initiation

  • Clinical Trial (NCT04418024) Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Polyneurophathy (ATTRibute-PN)

WHAT IS THE NEXT CATALYST EVENT?

  • Phase 3 Intitation

WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • H2 2020


PRIOR DATA/EVENTS

PRESS RELEASES

Updated by MV

ATTRibute-PN, ATTR,  Transthyretin amyloidosis (ATTR), Eidos, EIDX, systemic disease

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon